-

Rion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ROCHESTER, Minn.--(BUSINESS WIRE)--Rion, a leader in regenerative medicine and exosome technology, today announced Dr. Atta Behfar, Co-Founder, will present at the 42nd Annual JP Morgan Healthcare Conference on Wednesday, January 10, 2024, at 02:00 PM. The presentation will showcase Rion's breakthrough developments in platelet-derived regenerative exosome technology and its significant impact across various regenerative medicine therapeutic areas.

“I am honored to be presenting at the JP Morgan Healthcare Conference, and to have the opportunity to share with other industry leaders our breakthrough regenerative exosome technology as we build a new therapeutic platform," said Dr. Atta Behfar, Co-Founder of Rion. "This platform allows us to highlight Rion's significant contributions to regenerative medicine and discuss our innovative regenerative exosome technology with a global audience.”

About Rion

Rion is a clinical-stage regenerative medicine company focused on developing innovative exosome therapeutics based on platelet-derived regenerative exosomes. Rion has built a proprietary exosome engineering and manufacturing platform for Platelet Exosome Product (PEPTM), an innovative and commercially viable biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine. RION was established in 2017 and is headquartered in Rochester, Minnesota.

Contacts

Scott McCrea at mccrea@riontx.com

Industry:

Rion

Release Versions
English

Contacts

Scott McCrea at mccrea@riontx.com

More News From Rion

RION Announces First Patient Enrolled in Phase 1b Clinical Study Evaluating Purified Exosome Product™ (PEP™) for Knee Osteoarthritis

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, today announced the enrollment of the first patient in its Phase 1b clinical study evaluating Purified Exosome Product™ (PEP™) for the treatment of Knee Osteoarthritis (OA). This milestone highlights RION’s commitment to advancing innovative regenerative therapies that address unmet medical needs. Knee Osteoarthritis is the most common form of arthritis, affect...

RION Announces Final Patient Enrolled in the Phase 2 Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company at the forefront of exosome-based therapeutics, announced today that it has completed patient enrollment in its Phase 2 clinical trial for Purified Exosome Product™ (PEP™) in the treatment of Diabetic Foot Ulcers (DFUs). This milestone marks a significant step forward in the company’s mission to develop cutting-edge therapies addressing chronic wound care. The multi-center, prospective, open-label study enro...

RION to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ROCHESTER, Minn.--(BUSINESS WIRE)--RION, a clinical-stage regenerative medicine company revolutionizing healthcare through its exosome-based technology, announced today that its Co-Founder, Dr. Atta Behfar, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 10:00 AM PST. Dr. Behfar will showcase RION’s groundbreaking Purified Exosome Product™ (PEP™), a proprietary therapeutic platform designed to harness the power of exosomes to address unmet nee...
Back to Newsroom